RECOVERY Trial
University of Oxford
  • Site Map
  • Accessibility
  • Cookies
  • Log in
  • Home
  • For patients
  • For Site Staff
  • Results
  • News
  • International
  • Case studies
  1. Results
  2. Baricitinib results

Baricitinib results

press release

3 March 2022

Baricitinib reduces deaths in patients hospitalised with COVID-19

publications

The preliminary results of the baricitinib comparison have been published on medRxiv.


© 2022 Nuffield Department of Population Health
  • Freedom of Information
  • Privacy Policy
  • Copyright Statement
  • Logo for the Nuffield Department of Medicine
  • Logo for Oxford Population Health
  • Site Map
  • Accessibility
  • Cookies
  • Log in
  • Welcome
  • For patients
    • Why is this research being done?
    • What is the purpose of this study?
    • Who is doing the study?
    • Who is being included in the study?
    • What happens next if I agree to be included in this study?
    • What are the possible benefits of being in the study?
    • What are the possible risks of being in the study?
    • Can I stop the study treatment or my participation early?
    • If I have any questions or problems, who can I call?
    • What information do you hold about me and how do you keep it private?
    • Do I have to take part?
    • Are there any financial costs or payments?
    • What else can you tell me?
    • What about my data privacy?
    • Videos
    • RECOVERY trial participant newsletter opt-out
    • RECOVERY trial participant newsletter sign-up
    • RECOVERY trial participant newsletter opt-out
    • What is dimethyl fumarate and why is it being tested?
    • What are the potential risks of this part of the study?
    • What are the extra assessments being done?
    • Can I stop the study treatment or my participation early?
    • Do I have to take part?
  • For Site Staff
    • For Site Staff
    • Pharmacy
    • Site Set-Up
      • RECOVERY Trial FAQs for sites
      • Site set-up
      • Data Monitoring Committee correspondence
      • Regulatory documents
      • Safety and Annual Reports
    • Training
      • Training for site staff
      • Background and informed consent
      • 1st and 2nd randomisation
      • Children and neonates
      • Follow-up
      • Immunomodulatory Therapies
      • Other oral therapies
      • Influenza treatments
      • Antivirals for COVID-19
    • site teams
    • Follow-up data collection
    • Randomisation
    • Randomisation Training Confirmation
    • Background & Consent Training Confirmation
    • Children & Neonates Training Confirmation
    • Convalescent Plasma Training Confirmation
    • Monoclonal Antibodies Training Confirmation
    • Immunomodulatory Therapies Training Confirmation
    • Follow-up Training Confirmation
    • Dimethyl Fumarate Training Confirmation
    • High-dose Corticosteroids Training Confirmation
    • Other Oral Therapies Training Confirmation
    • Background Training Confirmation
    • Consent Training Confirmation
    • Influenza Treatments Confirmation Form
    • Sotrovimab Training Confirmation
    • Molnupiravir Training Confirmation
    • Paxlovid Training Confirmation
  • Results
    • Results
    • Dexamethasone results
    • Hydroxychloroquine results
    • Lopinavir-Ritonavir results
    • Study Protocol Archive
    • Azithromycin results
    • Convalescent Plasma results
    • Tocilizumab results
    • Colchicine results
    • Aspirin results
    • Regeneron's monoclonal antibody combination results
    • Baricitinib results
  • News
  • International
    • International sites
    • Indonesia
    • Nepal
    • Vietnam
    • Ghana
    • India
    • South Africa
  • Case studies